DrugPatentWatch Database Preview
CLINICAL TRIALS PROFILE FOR ORASONE
Clinical Trials for Orasone
| Trial ID | Title | Status | Sponsor | Phase | Summary |
|---|---|---|---|---|---|
| NCT00550550 | Efficacy and Safety of Grass Sublingual Tablet in Children and Adolescents (P05239 AM3)(COMPLETED) | Completed | Merck Sharp & Dohme Corp. | Phase 3 | The purpose of the study is to investigate the efficacy and safety of a grass sublingual tablet in children and adolescents with a history of grass-pollen induced rhinoconjunctivitis with or without asthma. |
| NCT00562159 | Efficacy and Safety of Grass Sublingual Tablet in Adults (P05238 AM3)(COMPLETED) | Completed | Merck Sharp & Dohme Corp. | Phase 3 | This purpose of this study is to determine the efficacy and safety of a grass sublingual (under-the-tongue) tablet. |
| NCT03023046 | Etoposide, Prednisone, Vincristine Sulfate, Cyclophosphamide, and Doxorubicin in Treating Patients With Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma | Recruiting | National Cancer Institute (NCI) | Phase 2 | This phase II trial studies how well etoposide, prednisone, vincristine sulfate, cyclophosphamide, and doxorubicin (DA-EPOCH) works in treating patients with acute lymphoblastic leukemia or lymphoblastic lymphoma. Drugs used in chemotherapy, such as etoposide, prednisone, vincristine sulfate, cyclophosphamide, and doxorubicin, work in different ways to stop the growth of cancer cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. |
| NCT03023046 | Etoposide, Prednisone, Vincristine Sulfate, Cyclophosphamide, and Doxorubicin in Treating Patients With Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma | Recruiting | University of Washington | Phase 2 | This phase II trial studies how well etoposide, prednisone, vincristine sulfate, cyclophosphamide, and doxorubicin (DA-EPOCH) works in treating patients with acute lymphoblastic leukemia or lymphoblastic lymphoma. Drugs used in chemotherapy, such as etoposide, prednisone, vincristine sulfate, cyclophosphamide, and doxorubicin, work in different ways to stop the growth of cancer cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. |
| NCT03036904 | Study of Venetoclax Plus DA-EPOCH-R for the Treatment of Aggressive B-Cell Lymphomas | Recruiting | Genentech, Inc. | Phase 1 | This is a phase I, open label, single-arm, multi-center, dose-finding study of venetoclax in combination with DA-EPOCH-R in patients with aggressive B-Cell Lymphomas. |
| NCT03036904 | Study of Venetoclax Plus DA-EPOCH-R for the Treatment of Aggressive B-Cell Lymphomas | Recruiting | M.D. Anderson Cancer Center | Phase 1 | This is a phase I, open label, single-arm, multi-center, dose-finding study of venetoclax in combination with DA-EPOCH-R in patients with aggressive B-Cell Lymphomas. |
| Trial ID | Title | Status | Sponsor | Phase | Summary |
Clinical Trial Conditions for Orasone
Condition Name
| Condition Name for Orasone | |
| Intervention | Trials |
| Diffuse Large B-Cell Lymphoma | 3 |
| CD20 Positive | 2 |
| High Grade B-Cell Lymphoma With MYC and BCL2 and/or BCL6 Rearrangements | 2 |
| Clinical Stage IV Cutaneous Melanoma AJCC v8 | 2 |
| [disabled in preview] | 0 |
| This preview shows a limited data set Subscribe for full access, or try a Trial | |
Export unavailable in trial.
Subscribe for complete access.
Condition MeSH
Clinical Trial Locations for Orasone
Trials by Country
Clinical Trial Progress for Orasone
Clinical Trial Phase
Clinical Trial Sponsors for Orasone
Sponsor Name
